A Phase 4 interventional study of PCV13 and PPSV23 in Asthma, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 19 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-11-05.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,695 studies in Asthma with a site in United States — 134 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.
Among the 1,695 studies in Asthma with a site in United States, this one is the 1,178th largest by enrollment of the 1,353 interventional ones that give a count, is one of 83 that started in 2017, is one of 158 in phase 4, and was the 1,174th registered.
4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →134 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 12–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,695 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 337 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 83 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 79 across 3,345 interventional studies indexed under Asthma.
Median enrollment 100 across the 1,353 interventional studies, 112 across the 330 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
642 of 1,695 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,271 studies on the registry; 671 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 5 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
85 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,695 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone (Active comparator). At the Week 0 time point, the patients will receive either PCV13 (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype titers as well as a blood draw at week 16 and week 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23
Biological: PCV13 · Biological: PPSV23
Participants randomized to receive PPSV23 alone
Biological: PPSV23
Single 0.5 ml dose of PCV13 administered via intramuscular injection
Also known as: Prevnar
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
Also known as: Pneumovax
Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16
5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.
Time frame: Baseline, week 0, week 8, week 16
Sum of Anti-pneumococcal IgG to All Serotypes at Baseline, Week 0, Week 8 and Week 16
5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.
Time frame: Baseline, week 0, week 8, week 16
Sum of Anti-pneumococcal IgG to Serotypes Common to PCV13 and PPSV23 at Baseline, Week 0, Week 8, Week 16
5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 \& PPSV23. Measured as mcg/mL.
Time frame: Baseline, week 0, week 8, week 16
Sum of Anti-pneumococcal IgG to Serotypes Unique to PPSV23 at Baseline, Week 0, Week 8 and Week 16.
5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.
Time frame: Baseline, week 0, week 8, week 16
| Milestone | PCV13 and PPSV23 | PPSV23 |
|---|---|---|
| Started | 8 | 9 |
| Completed | 8 | 9 |
| Not completed | 0 | 0 |
5 ml blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/dL.
| mcg/dL | PCV13 and PPSV23 | PPSV23 |
|---|---|---|
| baseline | 109.8 (74.3 to 141.8) | 53.9 (34.8 to 185.3) |
| week 0 | 142.3 (111.7 to 194.6) | 53.9 (34.8 to 185.3) |
| week 8 | 211.7 (184.6 to 271.0) | 243.3 (173.4 to 271.0) |
| week 16 | 212.0 (171.1 to 257.7) | 224.8 (196.6 to 271.0) |
5 ml blood draw for assessment of IgG specific Antibody titers to all 23 serotypes. Measured as mcg/mL.
| mcg/mL. | PCV13 and PPSV23 | PPSV23 |
|---|---|---|
| baseline | 228.0 (174.2 to 362.3) | 206.8 (130.1 to 323.8) |
| week 0 | 506.3 (349.6 to 670.9) | 206.8 (130.1 to 323.8) |
| week 8 | 502.9 (369.9 to 790.5) | 449.4 (338.7 to 583.4) |
| week 16 | 534.8 (325.4 to 688.4) | 485.7 (321.2 to 588.6) |
5 ml blood draw for assessment of IgG specific Antibody titers for serotypes common PCV13 \& PPSV23. Measured as mcg/mL.
| mcg/mL | PCV13 and PPSV23 | PPSV23 |
|---|---|---|
| baseline | 142.4 (110.7 to 246.8) | 107.4 (92.9 to 161.8) |
| week 0 | 418.9 (303.2 to 525.1) | 107.4 (92.9 to 161.8) |
| week 8 | 362.8 (258.9 to 498.6) | 229.4 (162.6 to 302.2) |
| week 16 | 343.7 (221.5 to 447.1) | 230.5 (149.5 to 302.1) |
5 ml blood draw for assessment of IgG specific Antibody titers for serotypes unique to PPSV23. Measured as mcg/mL.
| mcg/mL | PCV13 and PPSV23 | PPSV23 |
|---|---|---|
| baseline | 89.2 (64.1 to 120.9) | 74.7 (41.0 to 160.2) |
| week 0 | 82.4 (56.2 to 152.4) | 74.7 (41.0 to 160.2) |
| week 8 | 174.2 (92.3 to 283.4) | 220.0 (164.7 to 246.8) |
| week 16 | 179.1 (96.9 to 277.0) | 184.1 (171.0 to 255.2) |
Collected over Adverse Events were collected from baseline to end of study, approximately 16 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PCV13 and PPSV23 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| PPSV23 | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Age, Categorical(Participants) | PCV13 and PPSV23 | PPSV23 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 16 |
| >=65 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | PCV13 and PPSV23 | PPSV23 | Total |
|---|---|---|---|
| Female | 7 | 8 | 15 |
| Male | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | PCV13 and PPSV23 | PPSV23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 8 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | PCV13 and PPSV23 | PPSV23 | Total |
|---|---|---|---|
| United States | 8 | 9 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2020, 38 months.
Results were first posted in Nov 2021, 10 months after primary completion.
Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 38 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine